Liposome-encapsulated progesterone efficiently suppresses B-lineage cell proliferation

• Published in: Biochemistry and biophysics reports 2024-07, Vol.38, p.101710-101710, Article 101710
• Main Authors: Seki, Toshiro, Suzuki, Rikio, Ohshima, Shino, Manabe, Yoshiyuki, Onoue, Shion, Hoshino, Yuki, Yasuda, Atsushi, Ito, Ryoji, Kawada, Hiroshi, Ishimoto, Hitoshi, Shiina, Takashi, Kametani, Yoshie
• Format: Article
• Language: English
• Subjects: B cell lymphoma; Liposome; Myeloma; Progesterone; Short Communication
• ISSN: 2405-5808; 2405-5808
• DOI: 10.1016/j.bbrep.2024.101710

Progesterone suppresses several ancient pathways in a concentration-dependent manner. Based on these characteristics, progesterone is considered a candidate anticancer drug. However, the concentration of progesterone used for therapy should be higher than the physiological concentration, which makes it difficult to develop progesterone-based anticancer drugs. We previously developed liposome-encapsulated progesterone (Lipo-P4) with enhanced anticancer effects, which strongly suppressed triple-negative breast cancer cell proliferation in humanized mice. In this study, we aimed to clarify whether Lipo-P4 effectively suppresses the proliferation of B-lineage cancer cells. We selected six B-cell lymphoma and two myeloma cell lines, and analyzed their surface markers using flow cytometry. Next, we prepared liposome-encapsulated progesterone and examined its effect on cell proliferation in these B-lineage cancer cells, three ovarian clear cell carcinoma cell lines, two prostate carcinoma cell lines, and one triple-negative breast cancer adenocarcinoma cell line. Lipo-P4 suppressed the proliferation of all cancer cell lines. All B-lineage cell lines, except for the HT line, were more susceptible than the other cell types, regardless of the expression of differentiation markers. Empty liposomes did not suppress cell proliferation. These results suggest that progesterone encapsulated in liposomes efficiently inhibits the proliferation of B-lineage cells and may become an anticancer drug candidate for B-lineage cancers. •Progesterone (P4) suppresses cancer cell proliferation dose-dependently.•This effect is stronger with liposome-encapsulated P4 (Lipo-P4).•B-lineage cells are highly susceptible to Lipo-P4.•Lipo-P4 is a good candidate drug targeting B-lineage cancer cells.